News

03 Mar 2017

ReproCELL Europe's CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research

ReproCELL Europe's CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer using techniques such as 3D models, PDX systems and precision-cut tumour slices.
Read More >>

14 Feb 2017

ReproCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan

ReproCELL Inc. (Japan)s CEO Dr Chikafumi Yokoyama had the honour of meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government, during her visit to the Scottish Enterprise Tokyo office, today (14 February 2017).
Read More >>

07 Feb 2017

Scottish Enterprise Association Honours ReproCELL with Annual Awards Nomination

Scottish Enterprise Association Honours ReproCELL with Annual Awards Nomination
Read More >>

20 Jan 2017

Job vacancy: Clinical Alliances Manager

We wish to recruit a Clinical Alliances Manager to grow and manage our clinical network of hospitals, tissue banks and organ procurement organisations. The Clinical Alliances Manager ensures that sufficient donations of tissue are received to support ReproCELLs research on new medicines and to ensure compliance with relevant legal and regulatory requirements.
Read More >>

1 2 3 4 >>

ReproCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan

14/02/2017

ReproCELL Inc. (Japan)’s CEO Dr Chikafumi Yokoyama had the honour of meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government, during her visit to the Scottish Enterprise Tokyo office, today (14 February 2017).



At the meeting Dr Yokoyama gave a presentation introducing Ms Hyslop to ReproCELL and its European activities. He highlighted ReproCELL Europe Ltd’s Advanced Drug Discovery Center, which is based in Glasgow, Scotland, and its research in personalized medicines.

 

Live chat by BoldChat